Kumaran Deiva

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6419513/publications.pdf

Version: 2024-02-01

71 papers

3,654 citations

28 h-index

186265

58 g-index

74 all docs

74 docs citations

74 times ranked 3433 citing authors

#	Article	IF	CITATIONS
1	Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. JAMA Neurology, 2018, 75, 478.	9.0	306
2	Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology, 2014, 83, 142-150.	1.1	275
3	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	10.2	261
4	Intracerebral Administration of Adeno-Associated Viral Vector Serotype rh.10 Carrying Human <i>SGSH</i> and <i>SUMF1</i> cDNAs in Children with Mucopolysaccharidosis Type IIIA Disease: Results of a Phase I/II Trial. Human Gene Therapy, 2014, 25, 506-516.	2.7	213
5	Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e81.	6.0	205
6	<i>N</i> â€methylâ€ <i>D</i> â€aspartate receptor antibodies in postâ€"herpes simplex virus encephalitis neurological relapse. Movement Disorders, 2014, 29, 90-96.	3.9	192
7	Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial. Lancet Neurology, The, 2017, 16, 712-720.	10.2	149
8	Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease. Annals of Neurology, 2021, 89, 30-41.	5.3	123
9	MOG antibody-related disorders: common features and uncommon presentations. Journal of Neurology, 2017, 264, 1945-1955.	3.6	119
10	CNS involvement at the onset of primary hemophagocytic lymphohistiocytosis. Neurology, 2012, 78, 1150-1156.	1.1	115
11	Treatment and outcome of children and adolescents with N-methyl-d-aspartate receptor encephalitis. Journal of Neurology, 2015, 262, 1859-1866.	3.6	105
12	Pediatric transverse myelitis. Neurology, 2016, 87, S46-52.	1.1	92
13	Use and Safety of Immunotherapeutic Management of <i>N</i> -Methyl- <scp>d</scp> -Aspartate Receptor Antibody Encephalitis. JAMA Neurology, 2021, 78, 1333.	9.0	91
14	E.U. paediatric MOG consortium consensus: Part 1 \hat{a} \in "Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 2-13.	1.6	87
15	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	6.0	70
16	Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology, 2013, 80, 2226-2232.	1.1	68
17	Glial Fibrillary Acidic Protein Autoimmunity. Neurology, 2022, 98, .	1.1	61
18	Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e188.	6.0	60

#	Article	IF	Citations
19	E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 41-53.	1.6	59
20	Acute idiopathic transverse myelitis in children. Neurology, 2015, 84, 341-349.	1.1	56
21	Fractalkine reduces N-methyl-d-aspartate-induced calcium flux and apoptosis in human neurons through extracellular signal-regulated kinase activation. European Journal of Neuroscience, 2004, 20, 3222-3232.	2.6	55
22	Cranial nerve involvement in patients with MOG antibody–associated disease. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e543.	6.0	53
23	Intrathecal treatment of antiâ€×i>Nà€Methylâ€ <scp>d</scp> â€aspartate receptor encephalitis in children. Developmental Medicine and Child Neurology, 2015, 57, 95-99.	2.1	48
24	Hashimoto's encephalopathy: Identification and long-term outcome in children. European Journal of Paediatric Neurology, 2013, 17, 280-287.	1.6	40
25	Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis. Journal of Neuroimmunology, 2015, 289, 1-7.	2.3	40
26	Treatment and outcome of aquaporin-4 antibody–positive NMOSD. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	37
27	Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms. Orphanet Journal of Rare Diseases, 2012, 7, 96.	2.7	33
28	Relapsing encephalopathy with cerebellar ataxia are caused by variants involving p.Arg756 in ATP1A3. European Journal of Paediatric Neurology, 2019, 23, 448-455.	1.6	33
29	Creatine and guanidinoacetate reference values in a French population. Molecular Genetics and Metabolism, 2013, 110, 263-267.	1.1	32
30	E.U. paediatric MOG consortium consensus: Part 2 – Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 14-21.	1.6	32
31	E.U. paediatric MOG consortium consensus: Part 4 – Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 32-40.	1.6	29
32	Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Journal of the Neurological Sciences, 2017, 381, 240-244.	0.6	29
33	Neurological outcome of patients with cryopyrin-associated periodic syndrome (CAPS). Orphanet Journal of Rare Diseases, 2017, 12, 33.	2.7	28
34	French recommendations for the management of Behçet's disease. Orphanet Journal of Rare Diseases, 2021, 16, 352.	2.7	27
35	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
36	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II. Multiple Sclerosis Journal, 2022, 28, 1562-1575.	3.0	25

3

#	Article	IF	Citations
37	E.U. paediatric MOG consortium consensus: Part 3 – Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology, 2020, 29, 22-31.	1.6	24
38	Acute Disseminated Encephalomyelitis: Current Perspectives. Children, 2020, 7, 210.	1.5	24
39	CCR5-, DC-SIGN-Dependent Endocytosis and Delayed Reverse Transcription after Human Immunodeficiency Virus Type 1 Infection in Human Astrocytes. AIDS Research and Human Retroviruses, 2006, 22, 1152-1161.	1.1	22
40	Consistent control of disease activity with fingolimod versus IFN \hat{I}^2 -1a in paediatric-onset multiple sclerosis: further insights from PARADIGMS. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 91, jnnp-2019-321124.	1.9	22
41	Charcot–Marie–Tooth disease misdiagnosed as chronic inflammatory demyelinating polyradiculoneuropathy: An international multicentric retrospective study. European Journal of Neurology, 2021, 28, 2846-2854.	3.3	22
42	Mild Encephalitis/Encephalopathy with reversible splenial lesion syndrome: An unusual presentation of anti-GFAP astrocytopathy. European Journal of Paediatric Neurology, 2020, 26, 89-91.	1.6	21
43	Clinical Trials for Gene Therapy in Lysosomal Diseases With CNS Involvement. Frontiers in Molecular Biosciences, 2021, 8, 624988.	3.5	21
44	Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome. Frontiers in Immunology, 2021, 12, 655478.	4.8	16
45	Catatonia and Autoimmune Conditions in Children and Adolescents: Should We Consider a Therapeutic Challenge?. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 167-176.	1.3	15
46	Fatigue, depression, and quality of life in children with multiple sclerosis: a comparative study with other demyelinating diseases. Developmental Medicine and Child Neurology, 2020, 62, 241-244.	2.1	15
47	Effects of SDF-1α and gp120IIIB on apoptotic pathways in SK-N-SH neuroblastoma cells. Neuroscience Letters, 2006, 399, 115-120.	2.1	14
48	Sudden and isolated Broca's aphasia: A new clinical phenotype of anti NMDA receptor antibodies encephalitis in children. European Journal of Paediatric Neurology, 2014, 18, 790-792.	1.6	14
49	Anti-MOG autoantibodies pathogenicity in children and macaques demyelinating diseases. Journal of Neuroinflammation, 2019, 16, 244.	7.2	14
50	Paediatric optic neuritis: factors leading to unfavourable outcome and relapses. British Journal of Ophthalmology, 2018, 102, 808-813.	3.9	13
51	Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaques. EBioMedicine, 2019, 47, 492-505.	6.1	13
52	Risk factors for academic difficulties in children with myelin oligodendrocyte glycoprotein antibodyâ€associated acute demyelinating syndromes. Developmental Medicine and Child Neurology, 2020, 62, 1075-1081.	2.1	13
53	Extracranial vertebral artery dissection in children: natural history and management. Neuroradiology, 2015, 57, 729-738.	2.2	12
54	Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	9

#	Article	IF	Citations
55	Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results. Human Gene Therapy, 2021, 32, 1251-1259.	2.7	9
56	Early-onset stroke with moyamoya-like syndrome and extraneurological signs: a first reported paediatric series. European Radiology, 2016, 26, 2853-2862.	4.5	7
57	Regulatory T Cells Increase After rh-MOG Stimulation in Non-Relapsing but Decrease in Relapsing MOG Antibody-Associated Disease at Onset in Children. Frontiers in Immunology, 2021, 12, 679770.	4.8	7
58	Imaging in Pediatric Multiple Sclerosis. Clinical Neuroradiology, 2021, 31, 61-71.	1.9	6
59	Progressive Leukodystrophy-Like Demyelinating Syndromes with MOG-Antibodies in Children: A Rare Under-Recognized Phenotype. Neuropediatrics, 2021, 52, 337-340.	0.6	6
60	Promoting physical activity to control multiple sclerosis from childhood. Neurology, 2015, 85, 1644-1645.	1.1	5
61	Acute transverse myelitis following an opsoclonus-myoclonus syndrome: An unusual presentation. European Journal of Paediatric Neurology, 2018, 22, 878-881.	1.6	5
62	Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study. Multiple Sclerosis Journal, 2021, 27, 922-932.	3.0	5
63	Pediatric onset multiple sclerosis: Future challenge for early diagnosis and treatment. Presse Medicale, 2021, 50, 104069.	1.9	5
64	Current international trends in the treatment of multiple sclerosis in childrenâ€"Impact of the COVID-19 pandemic. Multiple Sclerosis and Related Disorders, 2021, 56, 103277.	2.0	5
65	Obesity in Pediatric-Onset Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, e1044.	6.0	4
66	Effect of fingolimod on health-related quality of life in paediatric patients with multiple sclerosis: results from the phase 3 PARADIG <i>MS</i> Study. BMJ Neurology Open, 2022, 4, e000215.	1.6	4
67	Neurological involvement in secondary hemophagocytic lymphohistiocytosis in children. European Journal of Paediatric Neurology, 2021, 34, 110-117.	1.6	3
68	Fulminant toxic shock syndrome following rituximab therapy in an 11-year-old boy. Journal of Neurology, 2013, 260, 2892-2893.	3.6	2
69	Febrile Brain Stroke and Tuberculous Meningitis: Persisting Threat in Non-Endemic Countries. Neuropediatrics, 2010, 41, 273-275.	0.6	1
70	Vessel Wall Contrast Enhancement on Magnetic Resonance Imaging May Be Suggestive for Future Development of Further Arterial Changes. Canadian Journal of Neurological Sciences, 2016, 43, 728-730.	0.5	1
71	Early and aggressive treatment may modify anti Hu associated encephalitis prognosis. Neuropediatrics, 0, , .	0.6	0